Radiopharmaceuticals PLUVICTO / LUTATHERA - Nuclear Med, IND

Notice of Intent to Sole Source Requirement The Department of Veterans Affairs, VA Healthcare System, Network 10 Contracting Office intends to negotiate a sole source contract for a FDA approved radioactive therapy drug under the authority of GSAR 538.7104-3(b)(1)(ii): Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized. The associated NAICS code for this is 325412. The vendor will be Novartis, Route 10, East Hanover, NJ, 07936. Description of services:

SUPPLY: This is a new FDA approved radioactive therapy drug. The therapeutic effectiveness of this radioactive drug has changed standard patient care guidelines and now patients diagnosed with prostate cancer are recommended to have Lu177 PLUVICTO as a treatment option. Also needed is the purchase of the Lu177 LUTATHERA. A One Year firm fixed price contract shall be awarded. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement.

It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. It is not a solicitation or request for offers.